Cancer researchers at Perth's The Kids for Child Health Research (TICHR) have developed a new test that can rapidly detect the loss of genes in cancer cells, paving the way for more targeted and effective treatments for patients.
Australian Cancer Technology (AustCancer, ASX:ACU) today announced that it has entered into a partnership agreement with the Institute to commercialise this novel technology and bring it to the market as quickly as possible.
Professor Ursula Kees, who heads the Children's Leukaemia and Cancer Research Division at TICHR, said the development of a fast, simple gene test could significantly improve patient outcomes.
"Our research in a group of cancer patients has shown that those patients with cancer cells that have lost a specific tumour suppressor gene are at greater risk of relapse," she said.
"If their doctors can determine the genetic makeup of the cancer at an early stage, then they will have a very important indicator of the type of treatment that will be most effective.
"Current methods for testing the loss of genes in cancer cells are expensive and relatively slow. The new technology that we have developed is fast, simple and can be applied at low cost - in fact it uses standard equipment found in most diagnostic labs."
Professor Kees said in studies on children with acute lymphoblastic leukaemia (ALL), which were published in the prestigious journal 'Blood', her team had shown that this technology is effective in measuring the deletion of an important tumour suppressor gene. The studies also showed that the gene's absence pointed to a 11-fold higher risk of relapse.
"Testing cancer cells to determine whether a gene is missing has always been considered very difficult because patient specimens always contain normal cells, and the genetic differences that we're looking for are very subtle. This new technology can detect those very small differences."
Paul Hopper, managing director of AustCancer said his company would be determining the most appropriate commercial model by which the test can be rapidly brought to the market.
"We believe that, as medical science's understanding of the role of genes in cancer grows, an inexpensive, quick and routine gene test will become essential in the diagnosis of many types of cancer. The technology is patented and we have embarked on a research program with the Institute to expand its utility to other important cancer genes."
Director of The Kids for Child Health Research, Professor Fiona Stanley, said the Institute was delighted to partner with AustCancer on this discovery because of their strong credentials in the field.
"It's important that we make sure that the benefits of our research are seen by the patients as soon as possible. This partnership will ensure that we can now take this discovery to the next stage of development."
--Ends--
About The Kids for Child Health Research
The Institute has enjoyed over a decade of research activity and has been responsible for a number of key findings and initiatives. The Institute's mission is to improve the health of children through the development and application of research into the causes and prevention of ill health and the maintenance of health.
About Australian Cancer Technology
Australian Cancer Technology is a broadly based international oncology company focused on developing and delivering products for the unmet needs of cancer patients. Its leading edge PentrixTM anti-cancer vaccine successfully completed Phase 1a and Phase 1b/2a trials at St Vincent's Hospital Sydney and will undergo a comprehensive Phase 2 trial with prostate cancer patients at leading Melbourne institutions late in 2003.
Its US subsidiary, NuraPlex, is launching a range of nutritional supplements designed by leading US medical scientists to complement traditional treatments for cancer patients. A new oncology drug (CHK1 Kinase Inhibitor) to optimise the efficacy of chemotherapy and radiotherapy is also being developed with Cambridge UK joint venture partner BioFocus plc.